ADTXNCMHealthcare·Biotechnology#590 in industry

Aditxt, Inc.

-96.8% · 90d

$0.25

-0.03 (-11.89%)

After-Hours $0.23(-0.02)

News

(1)

April 2026

Apr 3, 20263 weeks agoDEF 14AHealthcare

Aditxt, Inc. — DEF 14A Filing

ADTXAditxt, Inc.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Aditxt, Inc. It's an official notice and information packet sent to shareholders before an annual meeting. Its purpose is to get shareholders to vote on important company matters. This document outlines what those matt

Read summaryView on SEC EDGAR

Key Data

Market Cap$225,212

Open$0.25

Prev Close$0.28

Day Range$0.22 – $0.25

52W Range$0.22 – $2495.04

Volume25,766,885

P/E (TTM)—

EPS$-9230.64

Dividend Yield—

Beta1.40

Revenue Growth-86.60%

About

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Healthcare · Biotechnology

www.aditxt.com